JP2020122023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020122023A5 JP2020122023A5 JP2020089453A JP2020089453A JP2020122023A5 JP 2020122023 A5 JP2020122023 A5 JP 2020122023A5 JP 2020089453 A JP2020089453 A JP 2020089453A JP 2020089453 A JP2020089453 A JP 2020089453A JP 2020122023 A5 JP2020122023 A5 JP 2020122023A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- unit
- subscript
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CNc(c(*)c(COC)c(*)c1*)c1O* Chemical compound CNc(c(*)c(COC)c(*)c1*)c1O* 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007056A JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647373P | 2012-05-15 | 2012-05-15 | |
| US61/647,373 | 2012-05-15 | ||
| US201361770983P | 2013-02-28 | 2013-02-28 | |
| US61/770,983 | 2013-02-28 | ||
| US201361773067P | 2013-03-05 | 2013-03-05 | |
| US61/773,067 | 2013-03-05 | ||
| US13/799,244 US9504756B2 (en) | 2012-05-15 | 2013-03-13 | Self-stabilizing linker conjugates |
| US13/799,244 | 2013-03-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097123A Division JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007056A Division JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020122023A JP2020122023A (ja) | 2020-08-13 |
| JP2020122023A5 true JP2020122023A5 (enExample) | 2020-09-24 |
| JP7014856B2 JP7014856B2 (ja) | 2022-02-01 |
Family
ID=49584442
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512756A Active JP6423340B2 (ja) | 2012-05-15 | 2013-05-14 | 自己安定化リンカー結合体 |
| JP2018097123A Active JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
| JP2020089453A Expired - Fee Related JP7014856B2 (ja) | 2012-05-15 | 2020-05-22 | 自己安定化リンカー結合体 |
| JP2022007056A Active JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A Pending JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512756A Active JP6423340B2 (ja) | 2012-05-15 | 2013-05-14 | 自己安定化リンカー結合体 |
| JP2018097123A Active JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007056A Active JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A Pending JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2850094B1 (enExample) |
| JP (5) | JP6423340B2 (enExample) |
| KR (5) | KR102433686B1 (enExample) |
| CN (2) | CN108465112B (enExample) |
| AU (5) | AU2013263002C1 (enExample) |
| BR (1) | BR112014028222A2 (enExample) |
| CA (2) | CA2869777C (enExample) |
| EA (1) | EA037203B1 (enExample) |
| ES (1) | ES2983109T3 (enExample) |
| HK (1) | HK1207388A1 (enExample) |
| MX (2) | MX384366B (enExample) |
| NZ (3) | NZ724892A (enExample) |
| SG (2) | SG10201608904YA (enExample) |
| WO (1) | WO2013173337A2 (enExample) |
| ZA (1) | ZA201407369B (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2837840C (en) | 2011-06-10 | 2020-08-04 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| KR102433686B1 (ko) * | 2012-05-15 | 2022-08-19 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| ES2726850T3 (es) | 2013-10-11 | 2019-10-09 | Mersana Therapeutics Inc | Conjugados de proteína-polímero-fármaco |
| KR102572149B1 (ko) | 2013-10-11 | 2023-08-30 | 아사나 바이오사이언시스 엘엘씨 | 단백질-폴리머-약물 접합체 |
| KR102356814B1 (ko) * | 2013-10-15 | 2022-01-28 | 씨젠 인크. | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 |
| TWI727919B (zh) | 2013-12-19 | 2021-05-21 | 美商西雅圖遺傳學公司 | 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物 |
| WO2016008112A1 (en) * | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
| AU2015315007C1 (en) * | 2014-09-11 | 2021-06-03 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
| EP3200829B1 (en) * | 2014-10-01 | 2023-12-06 | Medimmune, LLC | Method of conjugating a polypeptide |
| US10377837B2 (en) | 2014-10-24 | 2019-08-13 | Nof Corporation | Antibody-drug conjugate having cyclic benzylidene acetal linker |
| AU2015358532C1 (en) * | 2014-12-03 | 2020-10-29 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| SG10201911585XA (en) * | 2014-12-09 | 2020-01-30 | Abbvie Inc | Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
| BR112017012342A2 (pt) * | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos |
| DK3270965T3 (da) * | 2015-03-18 | 2020-06-08 | Seattle Genetics Inc | Cd48-antistoffer og konjugater deraf |
| CN106267225B (zh) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
| CN111533778B (zh) * | 2015-07-28 | 2023-04-25 | 上海皓元生物医药科技有限公司 | 一种抗体偶联药物连接子的工业化生产方法 |
| TWI778491B (zh) | 2015-11-30 | 2022-09-21 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017096311A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
| SG11201807827VA (en) | 2016-03-25 | 2018-10-30 | Seattle Genetics Inc | Process for the preparation of pegylated drug-linkers and intermediates thereof |
| WO2017176648A1 (en) | 2016-04-04 | 2017-10-12 | Rutgers, The State University Of New Jersey | Topoisomerase poisons |
| CN109069665A (zh) * | 2016-05-10 | 2018-12-21 | 百时美施贵宝公司 | 具有增强的稳定性的微管溶素类似物的抗体-药物缀合物 |
| TWI762487B (zh) | 2016-06-08 | 2022-05-01 | 美商艾伯維有限公司 | 抗-b7-h3抗體及抗體藥物結合物 |
| AU2017277422A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
| MX2018015274A (es) | 2016-06-08 | 2019-10-07 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| US20190153108A1 (en) | 2016-06-08 | 2019-05-23 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
| CA3027047A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| WO2017214458A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| MX2018015285A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
| SG11201810970WA (en) | 2016-06-08 | 2019-01-30 | Abbvie Inc | Anti-egfr antibody drug conjugates |
| KR20190038579A (ko) * | 2016-08-09 | 2019-04-08 | 시애틀 지네틱스, 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
| WO2018075692A2 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| EP3559039A1 (en) | 2016-12-22 | 2019-10-30 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| MX2019010769A (es) | 2017-03-24 | 2019-12-11 | Seattle Genetics Inc | Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos. |
| CN107652219B (zh) | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
| MX2020001928A (es) | 2017-09-08 | 2020-03-24 | Seattle Genetics Inc | Proceso para la preparacion de tubulisinas e intermediarios de las mismas. |
| US11707531B2 (en) * | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| CN120795120A (zh) | 2018-06-05 | 2025-10-17 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| TW202519270A (zh) | 2018-06-07 | 2025-05-16 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| KR20210141918A (ko) * | 2018-12-21 | 2021-11-23 | 시아겐 인크. | 티올 다중 링커를 가진 adc |
| US20220233708A1 (en) * | 2019-06-28 | 2022-07-28 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof |
| KR20220079606A (ko) | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
| US20230173093A1 (en) * | 2020-04-10 | 2023-06-08 | Seagen Inc. | Charge variant linkers |
| US20230201358A1 (en) * | 2020-05-08 | 2023-06-29 | Mpeg La, L.L.C. | Linker compounds |
| CN114306633A (zh) * | 2020-09-29 | 2022-04-12 | 迈威(上海)生物科技股份有限公司 | 一种双取代桥连抗体偶联药物的制备方法 |
| JP7454110B2 (ja) | 2020-12-04 | 2024-03-21 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | 抗体薬物複合体、その中間体、製造方法及び使用 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| MX2024002571A (es) | 2021-09-03 | 2024-03-20 | Toray Industries | Composicion farmaceutica para tratamiento y/o prevencion de cancer. |
| AU2023234594A1 (en) | 2022-03-17 | 2024-09-19 | Seagen Inc. | Camptothecin conjugates |
| CN119486758A (zh) | 2022-06-30 | 2025-02-18 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| CN120417939A (zh) * | 2022-10-28 | 2025-08-01 | 伊莱利利公司 | 用于生物缀合的自水解马来酰亚胺 |
| WO2024108053A1 (en) | 2022-11-17 | 2024-05-23 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| CN120641134A (zh) * | 2023-02-09 | 2025-09-12 | 广州百济神州生物制药有限公司 | 自稳定接头缀合物 |
| WO2024220889A1 (en) | 2023-04-20 | 2024-10-24 | Seagen Inc. | Sting agonist compounds and conjugates thereof |
| AU2024304180A1 (en) | 2023-06-13 | 2026-01-08 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| TW202500198A (zh) * | 2023-06-29 | 2025-01-01 | 瑞士商百濟神州瑞士有限責任公司 | 生物活性偶聯物、其製備方法及用途 |
| WO2025054181A1 (en) | 2023-09-05 | 2025-03-13 | Seagen Inc. | Targeted degrader molecules and ligand drug conjugates thereof |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025264533A1 (en) | 2024-06-17 | 2025-12-26 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| FI102355B1 (fi) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5091542A (en) * | 1990-03-09 | 1992-02-25 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP0648240A1 (en) * | 1992-07-01 | 1995-04-19 | Akzo Nobel N.V. | Process for the modification of polyphenylene ether resin compositions |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| US5973166A (en) | 1998-03-02 | 1999-10-26 | The Dexter Corporation | Method for the preparation of maleimides |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| US7432331B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| PL2489364T3 (pl) | 2003-11-06 | 2015-06-30 | Seattle Genetics Inc | Związki monometylowaliny zdolne do sprzęgania do przeciwciał |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| CN114053429A (zh) | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| WO2007008603A1 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| NZ566982A (en) | 2005-09-26 | 2011-06-30 | Medarex Inc | Duocarmycin drug conjugates |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| PT2211904T (pt) | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
| ES2647927T3 (es) | 2008-03-18 | 2017-12-27 | Seattle Genetics, Inc. | Conjugados enlazadores del fármaco auriestatina |
| KR101892411B1 (ko) | 2008-04-30 | 2018-08-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| CA2745499A1 (en) * | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
| IL271761B (en) | 2009-02-05 | 2022-09-01 | Immunogen Inc | (12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepin-6-one, 4-benzyloxy-5-methoxy-2-nitrobenzoic acid and processes for preparing the same |
| CA2948693C (en) * | 2009-02-13 | 2018-09-04 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| NZ602241A (en) | 2010-04-15 | 2015-03-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| ES2730941T7 (es) * | 2010-10-22 | 2020-05-27 | Seattle Genetics Inc | Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR |
| CN113896731A (zh) | 2011-02-15 | 2022-01-07 | 伊缪诺金公司 | 细胞毒性苯并二氮杂䓬衍生物 |
| KR102433686B1 (ko) | 2012-05-15 | 2022-08-19 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| EP2968591A1 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
-
2013
- 2013-05-14 KR KR1020207022850A patent/KR102433686B1/ko active Active
- 2013-05-14 CN CN201810349815.9A patent/CN108465112B/zh active Active
- 2013-05-14 CN CN201380025771.XA patent/CN104822656B/zh active Active
- 2013-05-14 HK HK15108030.8A patent/HK1207388A1/xx unknown
- 2013-05-14 EP EP13791383.6A patent/EP2850094B1/en active Active
- 2013-05-14 KR KR1020237024059A patent/KR20230113821A/ko not_active Ceased
- 2013-05-14 WO PCT/US2013/040951 patent/WO2013173337A2/en not_active Ceased
- 2013-05-14 JP JP2015512756A patent/JP6423340B2/ja active Active
- 2013-05-14 EA EA201401254A patent/EA037203B1/ru unknown
- 2013-05-14 MX MX2019012201A patent/MX384366B/es unknown
- 2013-05-14 MX MX2014013807A patent/MX368678B/es active IP Right Grant
- 2013-05-14 SG SG10201608904YA patent/SG10201608904YA/en unknown
- 2013-05-14 NZ NZ724892A patent/NZ724892A/en not_active IP Right Cessation
- 2013-05-14 SG SG11201406252WA patent/SG11201406252WA/en unknown
- 2013-05-14 CA CA2869777A patent/CA2869777C/en active Active
- 2013-05-14 KR KR1020147034652A patent/KR102144069B1/ko active Active
- 2013-05-14 AU AU2013263002A patent/AU2013263002C1/en not_active Ceased
- 2013-05-14 KR KR1020227042635A patent/KR102557309B1/ko active Active
- 2013-05-14 CA CA3131619A patent/CA3131619A1/en not_active Abandoned
- 2013-05-14 KR KR1020217023061A patent/KR102475777B1/ko active Active
- 2013-05-14 BR BR112014028222A patent/BR112014028222A2/pt not_active Application Discontinuation
- 2013-05-14 NZ NZ74121113A patent/NZ741211A/en not_active IP Right Cessation
- 2013-05-14 NZ NZ630870A patent/NZ630870A/en not_active IP Right Cessation
- 2013-05-14 ES ES13791383T patent/ES2983109T3/es active Active
-
2014
- 2014-10-10 ZA ZA2014/07369A patent/ZA201407369B/en unknown
-
2018
- 2018-02-19 AU AU2018201190A patent/AU2018201190B2/en not_active Ceased
- 2018-05-21 JP JP2018097123A patent/JP6709247B2/ja active Active
-
2020
- 2020-04-28 AU AU2020202805A patent/AU2020202805B2/en not_active Ceased
- 2020-05-22 JP JP2020089453A patent/JP7014856B2/ja not_active Expired - Fee Related
-
2021
- 2021-03-16 AU AU2021201636A patent/AU2021201636B2/en not_active Ceased
-
2022
- 2022-01-20 JP JP2022007056A patent/JP7431261B2/ja active Active
-
2023
- 2023-05-15 AU AU2023203005A patent/AU2023203005A1/en not_active Abandoned
-
2024
- 2024-02-01 JP JP2024014096A patent/JP2024032941A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020122023A5 (enExample) | ||
| JP7512361B2 (ja) | Ｒｏｒ１抗体免疫複合体 | |
| JP7431261B2 (ja) | 自己安定化リンカー結合体 | |
| AU2023201373A1 (en) | Hydrophilic antibody-drug conjugates | |
| JP5314590B2 (ja) | カンプトテシン結合部分 | |
| JP2023082171A (ja) | 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート | |
| CN101969970B (zh) | 用抗体-药物偶联物联合治疗 | |
| CN112543752B (zh) | 连接子、含连接子的抗体偶联药物及连接子的用途 | |
| JP2015524796A5 (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| CN113874046B (zh) | 用于抗体-药物缀合物的含有糖苷的肽接头 | |
| JP7335957B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| KR20230008723A (ko) | 전하 변이체 링커 | |
| JP2005521389A5 (enExample) | ||
| JP2013505944A (ja) | Ｄｒ５リガンド薬物結合体 | |
| WO1997046260A1 (fr) | Complexes medicamenteux | |
| JP2009529522A (ja) | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 | |
| JP7057391B2 (ja) | タンパク薬物複合体で使用するためのリンカーに関連する材料および方法 | |
| JP3340127B2 (ja) | 異常増殖性疾患措置のための抗体接合体 | |
| JP2023541969A (ja) | 可溶性タグを有する分子および関連方法 | |
| JPWO2020200880A5 (enExample) | ||
| JP2024506300A (ja) | 免疫刺激化合物及びコンジュゲート体 | |
| JP2023159335A5 (enExample) | ||
| CA3121573A1 (en) | Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof | |
| JPH1192405A (ja) | 薬物複合体 | |
| JP2025525904A (ja) | 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート |